Healthcare resource utilization trends in patients with acute myeloid leukemia ineligible for intensive chemotherapy receiving first‐line systemic treatment or best supportive care: A multicenter international study

Author:

Ito Tomoki1ORCID,Sanford David2,Tomuleasa Ciprian3ORCID,Hsiao Hui‐Hua4,Olivera Leonardo José Enciso5,Enjeti Anoop Kumar67,Conca Alberto Gimenez8,del Castillo Teresa Bernal9ORCID,Girshova Larisa10,Martelli Maria Paola11,Guvenc Birol12,Bui Cat N.13,Delgado Alex14,Duan Yinghui13,Guijarro Belen Garbayo15,Llamas Cynthia13,Lee Je‐Hwan16

Affiliation:

1. First Department of Internal Medicine Kansai Medical University Hirakata Osaka Japan

2. Leukemia/Bone Marrow Transplant Program of BC Division of Hematology University of British Columbia Vancouver British Columbia Canada

3. Department of Hematology Ion Chiricuta Clinical Cancer Center Cluj‐Napoca Romania

4. Division of Hematology and Oncology Department of Internal Medicine Kaohsiung Medical University Hospital and Kaohsiung Medical University Kaohsiung Taiwan

5. Instituto Nacional de Cancerología Bogotá Colombia

6. Calvary Mater Newcastle University of Newcastle Waratah New South Wales Australia

7. NSW Health Pathology John Hunter Hospital New Lambton Heights New South Wales Australia

8. Section of Hematology Hospital Italiano de Buenos Aires Buenos Aires Argentina

9. University Hospital Central de Asturias ISPA, IUOPA Oviedo Spain

10. Federal State Budgetary Institution “Almazov National Medical Research Centre” of the Ministry of Health of the Russian Federation St Petersburg Russia

11. Department of Medicine and Surgery – Section of Hematology and Clinical Immunology Santa Maria della Misericordia” Hospital Perugia University Perugia Italy

12. Department of Hematology Cukurova University Adana Turkey

13. AbbVie, Inc. North Chicago Illinois USA

14. AbbVie, Inc. Singapore City Singapore

15. AbbVie, Inc. Madrid Spain

16. Department of Hematology Asan Medical Center University of Ulsan College of Medicine Seoul Korea

Funder

AbbVie

Publisher

Wiley

Subject

Hematology,General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3